Product Name: A-Raf (450-461) pT452+pT455+pS458
Product Number: PE-04ARS99
Size: 200 µg      Price:93.00
1 mg      $US187.00
Peptide Name: A-Raf (450-461) pT452+pT455+pS458

Product Use: This phosphopeptide may be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T-loop between subdomains VII and VIII. T452, T455 and S458 phosphorylation stimulates phosphotransferase activity.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: LA-pT-VK-pT-RW-pS-GAQ

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: βAla-Cys

Peptide Modifications Other: Phosphorylated

Peptide Molecular Mass Calculated: 1730.6 Da

Peptide Purity Percent after Synthesis and Purification: >95

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Scientific Background: A-Raf (RafA) is a protein-serine/threonine kinase of the TKL group and RAF family. It is involved in the transduction of mitogenic signals from the cell membrane receptors via Ras and MEK1/2 to the nucleus. It has been implicated in playing a role in the postsynaptic responses of hippocampal neuron. Phosphorylation of S214, S257, S262, S264, Y301, Y302, S432, T442, T452, T455 and S582 increases phosphotransferase activity. It is inhibited by Nexavar/Sorafenib (IC50>50 nM). A-Raf may be an oncoprotein (OP) based on its similarity to Raf1 and B-Raf. However, it does not display a higher than normal rate of mutation than most proteins in human tumours. The active form of the protein kinase acts to promote tumour cell proliferation.